Brexit votes creates EU regulatory uncertainty; Obama plans to veto health saving accounts bill; broad Entresto adoption could prevent more than 28,000 deaths
Medicare cost-cutting panel will not be activated this year; more Americans are abusing opioids; BIO blasts ICER
David Paragamian, previously of Huntsworth Health, is the new managing director of Razorfish Health.
Women use apps to get prescriptions for birth control; BMS names Gordon to chief commercial role; Takeda's Actos may halt progression of liver disease;
The agency has hired Sally Barton as head of the U.S. healthcare practice/
Cancer docs push HPV vaccine; GSK says experimental lung combo trumps Symbicort; Google rolls out new symptom search feature
A group of Havas agencies developed a song and a ritual for a Reckitt Benckiser campaign encouraging people to use mosquito repellant.
A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.
Novartis plans to launch five biosimilars; Making A Murderer directors will create project based on J&J investigation; Biogen plans to close or sell manufacturing plant
After the Orlando shooting, gay men were turned away from blood drives. A campaign explaining why had to reexamine its strategy
Drugmakers test out virtual reality, partner with companies like Spotify, and go for the cinematic at Cannes Lions.
McCann Health was named Network of the Year at the Cannes Lions Health festival of creativity in Cannes.
TBWA/WorldHealth worked with Galderma to get rid of the traditional process in which an agency and its client interact in effort to improve the work.
Ogilvy & Mather London developed the campaign, called Breathless Choir and set to Sting's "Every Breath You Take."
The Lions Health 2016 health and wellness category winners.
The Lions Health 2016 pharma category winners.
The shortlist for Lions Health 2016's pharma category.
The shortlist for Lions Health 2016's health and wellness category.
Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo
The jurors advanced 103 entries in the pharma category of Lions Health. U.S. agencies accounted for 16 of them.
A trial studying Keytruda met its endpoint in first-line lung cancer patients.
Betsy Neville, former senior partner and leader of the reputation management practice for the Americas at FleishmanHillard, has launched her own healthcare communications agency.
The discontinuation of the Take It From a Fish campaign can serve as an example of the common ups-and-downs of pharma marketing.
A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
Health and wellness entries are up 42% to 2,024 in 2016, compared to 1,430 in 2015, while pharma entries increased 35% to 583 this year.
According to research conducted in the first quarter, the healthcare products company has a sterling image with millennials despite a series of legal judgments against the company.
Remedy Health, taking a cue from Humans of New York, offers snapshots of patients' stories.
Sproutel CEO Aaron Horowitz talks about how Jerry the Bear came to life and why endocrinologists are stocking the bear in their offices.
Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug
On creativity: "Creativity can emerge from anywhere and anyone at any time. Medical breakthroughs aren't just discovered by scientists and researchers anymore."
Everything from the brand promise to the campaign solution to the case-study video — it all has to be based in authenticity, he says.
MM&M asks: What was the ROI for putting a McCann Health smiley face on the steps of the Palais?
A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs
Three executives shared some of the challenges women face in the workplace and how they want to shape the next generation of female leaders.
Her hire comes as the insurance giant is merging with Humana in a $37 billion deal.
The ability to pair data with a story or a human emotion is often easier for women,
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Most healthcare consumers are women, which makes it easier for female healthcare marketers to connect and understand their needs.
The health video startup ran a campaign in which it exchanged holiday cookbooks for email addresses.
Industry lobbying group plans counteroffensive; the FDA rejected a record high amount generic drug applications; adcomm recommends Pfizer painkiller
He talks about the three qualities that make for a great campaign and why conservatism will not help drugmakers address reputational issues.
BI launched a new gamified patient support program aimed at improving adherence to its COPD medication.
Bing can identify people with cancer symptoms; an experimental rheumatoid arthritis meets trial goals; the FDA updates compassionate use rules
Turnover in the company's salesforce for its flagship brand have led to disappointing sales, according to Valeant brass.
She discusses why it's wrong to compare the pharmaceutical industry to Skittles and why she expects to see more risk-taking in this year's creative work.
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
The healthcare agency promoted three executives to SVP and said a search for a new president is underway.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.
Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.
As Viagra goes generic, the pharma giant launches a feel-good corporate campaign.
Generic drugmakers consider pricing strategies; Mary Meeker predicts images and search will be half of online searches; drugmakers use comics to market
Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.
Pfizer releases new campaign; progressive research group calls out PCORI; U.S. drugmakers hire auditors they have ties with
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
New creative, account planning, and payer access talent lays groundwork for agency's first formal ex-Canada office.
Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.
WHO finds poor countries are paying too much for HCV drugs; Gilead faces a lawsuit over an HIV drug; BioMarin to stop developing Duchenne treatment
The agency underwent a reorganization just months after its parent company, Sudler & Hennessey, did the same.
Lawmaker calls for investigation of Purdue; Jazz to acquire Celator; Intercept's liver drug is approved
Although telehealth is still in its early stages, it's building momentum — with good reason.
Baby powder lawsuit impacts J&J's reputation; new bacterial infection raises concern about treatment options; Valeant reportedly rejected offer from Takeda
The unbranded campaign won the top prize at the 2015 Lions Health festival in Cannes.
BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Gilead announced that its head of commercial operations left the company.
Two recent polls paint a complicated picture of the public's opinion of the pharma industry.
Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller
A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
The FDA accepts Samsung's biosimilar for review; Sanofi retools executive committee; Entresto may get a boost from updated care guidelines
The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.
Pfizer brand teams competed in a shark-tank style challenge, with the winning teams receiving funding for their ideas.
Johnson & Johnson has appointed Michael Sneed, its worldwide VP of global corporate affairs, to the additional role of chief communications officer.
It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.
E.U. lifts warning on Pfizer's Chantix; Obama's Medicare Part B proposal panned by lawmakers; France to propose stricter rules for clinical trials
To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
The agency network said the private equity firm won't be involved in its day-to-day operations, but it will help its growth strategy.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
Health insurance provider Blue Cross Blue Shield Rhode Island drove engagement, leads, and conversion through its segmented campaigns.
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year
Tony Kingsley will oversee the company's daily operations and commercial activities.
Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.
A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.
Online doctors prescribe drugs without adequate warnings; House lawmakers to discuss Part B proposal; obesity drugs struggle for market share
The drugmaker said its rebate program will discount Nitropress and Isuprel, following a year of relentless criticism about the prices of the therapies.
It is the group's first acquisition since it was assembled in February under CEO Karen van Bergen.
Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill
"The Period Shop" is the first effort in a multi-year "Period Projects" campaign.
Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.
HCV market share battle is still underway; Regeneron CEO blasts criticism of Praluent's price; ProPublica database used to find docs to prescribe painkillers
Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.